This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (EXPLORE44)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05670730
Recruitment Status : Recruiting
First Posted : January 4, 2023
Last Update Posted : February 9, 2024
Sponsor:
Information provided by (Responsible Party):
Avidity Biosciences, Inc.

Brief Summary:

AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping.

Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers.

Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.


Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Exon 44 Drug: AOC 1044 Drug: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

AOC 1044-CS1 (EXPLORE44) is a 2-part study:

Part A: 5 cohorts with single ascending doses conducted in healthy adult volunteers

Part B: 3 cohorts with multiple ascending doses in participants with DMD mutations amenable to exon 44 skipping

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single and Multiple Ascending Doses of AOC 1044 Administered Intravenously to Healthy Adult Volunteers and Participants With DMD Mutations Amenable to Exon 44 Skipping
Actual Study Start Date : November 9, 2022
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2025


Arm Intervention/treatment
Experimental: AOC 1044-CS1 Part A - Single Dose Levels 1-5
AOC 1044 will be administered once.
Drug: AOC 1044
AOC 1044 will be administered via intravenous (IV) infusion

Placebo Comparator: AOC 1044-CS1 Part A - Single Dose: Placebo
Placebo will be administered once.
Drug: Placebo
Placebo will be administered via intravenous (IV) infusion.
Other Name: Saline

Experimental: AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3
AOC 1044 will be administered three times.
Drug: AOC 1044
AOC 1044 will be administered via intravenous (IV) infusion

Placebo Comparator: AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo
Placebo will be administered three times.
Drug: Placebo
Placebo will be administered via intravenous (IV) infusion.
Other Name: Saline




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Through study completion, up to Day 85 (Part A) or Day 169 (Part B) ]

Secondary Outcome Measures :
  1. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through Week 8 (Part A); Through Week 12 (Part B) ]
    Maximum plasma concentration (Cmax) of AOC 1044

  2. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through Week 8 (Part A); Through Week 12 (Part B) ]
    Terminal half-life (T1/2) of AOC 1044

  3. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through Week 8 (Part A); Through Week 12 (Part B) ]
    Area under the concentration-time curve (AUC) of AOC 1044

  4. PMO44 levels in skeletal muscle tissue [ Time Frame: Through Week 4 (Part A); Through Week 16 (Part B) ]
  5. Urine pharmacokinetic parameters [ Time Frame: Day 1-2 (0-24 hours after first dose) (Part A); Day 1-2 (0-24 hours after first dose) (Part B) ]
    Fraction of PMO44 excreted in urine

  6. Change from baseline in exon skipping as measured in skeletal muscle (Part B only) [ Time Frame: Baseline, Week 16 ]
  7. Absolute change from baseline in dystrophin protein level in skeletal muscle (Part B only) [ Time Frame: Baseline, Week 16 ]
  8. Percentage change from baseline in dystrophin protein level in skeletal muscle (Part B only) [ Time Frame: Baseline, Week 16 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Part A:

Key Inclusion Criteria:

  • Aged 18 to 55 years, inclusive, at the time of informed consent
  • Body mass index (BMI) of 18.5 to 32.0 kg/m2

Key Exclusion Criteria:

  • Clinically significant abnormalities in laboratory results, ECGs, or vitals
  • Current or recent use of prescription or nonprescription drugs
  • Positive drug/alcohol test at Screening or Day -1
  • Elevated blood pressure (BP) >130/80 mmHg at Screening
  • Participation in a clinical study in which an investigational product was received within 1 month of screening or 5 half-lives of the investigational product
  • Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply

Part B:

Key Inclusion Criteria:

  • Aged 7 to 27 years, inclusive, at the time of informed consent
  • Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years
  • Confirmation of DMD gene mutation amenable to exon 44 skipping
  • Weight ≥ 23 kg
  • Ambulatory or non-ambulatory

    • Ambulatory participants: LVEF ≥50% and FVC≥50%
    • Non-ambulatory participants: LVEF ≥45% and FVC≥40%
  • PUL 2.0 entry item A ≥3
  • If on corticosteroids, stable dose for 30 days before screening and throughout the study

Key Exclusion Criteria:

  • Biceps brachii muscles unsuitable for biopsy
  • Serum hemoglobin < lower limit of normal
  • Uncontrolled hypertension or diabetes
  • Prior treatment with any cell or gene therapy
  • Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent
  • Recently treated with an investigational drug
  • History of multiple drug allergies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05670730


Contacts
Layout table for location contacts
Contact: Avidity Biosciences, Inc. 858-771-7038 medinfo@aviditybio.com

Locations
Layout table for location information
United States, Arkansas
Arkansas Children's Recruiting
Little Rock, Arkansas, United States, 72202
Contact: Ashley Bryan         
United States, California
Stanford University Recruiting
Palo Alto, California, United States, 94304
Contact: Rabia Farooquee         
United States, Georgia
Rare Disease Research - Atlanta Recruiting
Atlanta, Georgia, United States, 30329
Contact: Laura Sutton         
United States, Massachusetts
University of Massachusetts Chan Medical School Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Sarah Figueira         
United States, Minnesota
Gillette Children's Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Laura Feldman         
United States, Ohio
Abigail Research Institute at Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43215
Contact: Regina Flomo         
United States, Texas
Worldwide Clinical Trials (Part A only) Active, not recruiting
San Antonio, Texas, United States, 78217
Sponsors and Collaborators
Avidity Biosciences, Inc.
Investigators
Layout table for investigator information
Study Director: Mark Stahl, MD, PhD Avidity Biosciences, Inc.
Layout table for additonal information
Responsible Party: Avidity Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT05670730    
Other Study ID Numbers: AOC 1044-CS1
First Posted: January 4, 2023    Key Record Dates
Last Update Posted: February 9, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Avidity Biosciences, Inc.:
EXPLORE44
Avidity Biosciences
Avidity
AOC 1044
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked